AP Biosciences

AP Biosciences Net Margin

The Net Profit Margin of AP Biosciences (6945.TWO) as of Nov 17, 2026 is -1,051.98 %. In the previous year, Net Profit Margin was -2,682.77 % — a change of -60.79% (higher).

Net Margin

-1,051.98 %

YoY

-60.79%

Last updated:

Net Profit Margin of AP Biosciences is 2023 -1,051.98 % . Net Profit Margin of AP Biosciences was 2022 -2,682.77 % . It decreases by -60.79% higher compared to the previous year.

AP Biosciences's net margin stands at -1,052.0%, down from 0.0% several years earlier.

The AP Biosciences Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2020
0.03 TWD
Jan 1, 2021
-2,682.77 TWD
Jan 1, 2023
-1,051.98 TWD
The AP Biosciences Net Margin history
YEARNet MarginYoY
-1,051.98 %-60.79%
-2,682.77 %-8.84 M%
0.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AP Biosciences Stock analysis

What does AP Biosciences do? AP Biosciences Inc generates revenue through the development and commercialization of protein and antibody drugs. The company focuses on early-stage drug candidates and preclinical trials, utilizing its technology platforms to create monoclonal and bispecific antibody drugs. Key products include IBI302, OmniMab, AP505, T-cube, and AP203, which target specific disease mechanisms and therapeutic areas. The primary buyers are pharmaceutical companies seeking to expand their drug pipelines through partnerships and licensing agreements. The firm's technology platforms, such as OmniMab fully human antibody library and T-cube, enable the development of novel bispecific antibodies. These platforms support the creation of drugs like AP505-PD-L1 x VEGF bispecific antibody and AP203-PD-L1 x CD137 fully human bispecific antibody, which are designed for specific therapeutic targets. The company's research and development efforts target diseases with high unmet medical needs, attracting interest from potential collaborators in the biopharmaceutical sector. AP Biosciences Inc's business model relies on advancing its pipeline of drug candidates through preclinical and clinical stages, with the goal of securing partnerships or licensing deals with larger pharmaceutical firms. The company's focus on bispecific antibody technology and its proprietary platforms positions it to generate revenue from milestone payments and royalties upon successful development and commercialization of its drug candidates. AP Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AP Biosciences stock

Net Profit Margin of AP Biosciences is -1,051.98 % in 2023.

Net Profit Margin of AP Biosciences changed from -2,682.77 % to -1,051.98 %, representing a -60.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin AP Biosciences since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's AP Biosciences with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — AP Biosciences

All Key Metrics — AP Biosciences